AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30964527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 139
Study 30964527 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vitamin D3
Number of subjects: 139
Study 28073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to rudeness (rude comments from the patient's mother)
Number of subjects: 39
Study 28073958 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral comments)
Number of subjects: 39
Study 28073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to rudeness with cognitive bias modification (CBM) intervention
Number of subjects: 39
Study 28073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to rudeness with narrative intervention
Number of subjects: 39
Study 28073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to rudeness
Number of subjects: 39
Study 26172084 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla-300)
Number of subjects: 629
Study 26172084 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/ml (Gla-100)
Number of subjects: 629
Study 26172084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 629
Study 23238658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild retinopathy
Number of subjects: 3433
Study 23238658 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe retinopathy
Number of subjects: 3433
Study 23238658 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of diabetic retinopathy at 4 years
Number of subjects: 3433
Study 21317434 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly
Number of subjects: 82
Study 21317434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 82
Study 19966913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1656
Study 19966913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1656
Study 16440531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily
Number of subjects: 45
Study 16440531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14687141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol
Number of subjects: 2357
Study 11174775 — intervention group
Group type: EXPERIMENTAL
Intervention: Claudication patients
Number of subjects: 2777
Study 9322456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cm H2O
Number of subjects: 9
Study 9322456 — intervention group
Group type: COMPARATOR
Intervention: No PSV (Control)
Number of subjects: 9
Study 8187975 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with adenoma
Number of subjects: 39
Study 8187975 — intervention group
Group type: COMPARATOR
Intervention: Men without adenoma
Number of subjects: 39
Study 8187975 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with adenoma
Number of subjects: 39
Study 8187975 — intervention group
Group type: COMPARATOR
Intervention: Women without adenoma
Number of subjects: 39
Study 8187975 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 39
Study 2444307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 5 mg/day
Number of subjects: 66
Study 2444307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg and 5 mg
Number of subjects: 66
Study 2444307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31296249 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions per week of acupuncture for 8 weeks
Number of subjects: 60
Study 31296249 — intervention group
Group type: COMPARATOR
Intervention: 1 session per week of acupuncture for 8 weeks
Number of subjects: 60
Study 28414488 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Self-Injurious Behaviors (T-SIB); n = 15
Number of subjects: 33
Study 28414488 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual; n = 18
Number of subjects: 33
Study 25902141 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating group
Number of subjects: 115
Study 25902141 — intervention group
Group type: COMPARATOR
Intervention: Exposure group
Number of subjects: 115
Study 25902141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 23369948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac hypothermia (myocardial temperature between 18-28 °C during ACC)
Number of subjects: 40
Study 23369948 — intervention group
Group type: COMPARATOR
Intervention: Cardiac normothermia (myocardial temperature over 34 °C during ACC)
Number of subjects: 40
Study 21518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 3451
Study 21518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-fatty acid 18:1 (TFA 18:1)
Number of subjects: 3451
Study 21518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-fatty acid 18:2 (TFA 18:2)
Number of subjects: 3451
Study 19092613 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 102
Study 19092613 — intervention group
Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 102
Study 16418308 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) 850 mg/m2 intravenously every 4 weeks
Number of subjects: 108
Study 16418308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination subcutaneously at 2-week intervals for first five vaccinations, then every 4 weeks
Number of subjects: 108
Study 16418308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination
Number of subjects: 108
Study 16418308 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) chemotherapy
Number of subjects: 108
Study 15105682 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (initiated before 72 hours after injury)
Number of subjects: 17
Study 15105682 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (initiated more than 120 hours after injury)
Number of subjects: 17
Study 15105682 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 17
Study 15105682 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 17
Study 11688002 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (6 x 10(6) KIU)
Number of subjects: 30
Study 11688002 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously)
Number of subjects: 30
Study 11688002 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study 9055050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication by five independent adjudicators
Number of subjects: 0
Study 9055050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication by two or three independent adjudicators
Number of subjects: 0
Study 9055050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication by a single independent adjudicator
Number of subjects: 0
Study 9055050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication process
Number of subjects: 0
Study 7955182 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus antithrombin III (250 U heparin + 25 U antithrombin III per minute)
Number of subjects: 615
Study 7955182 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (250 U heparin per minute)
Number of subjects: 615
Study 7955182 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus antithrombin III
Number of subjects: 615
Study 7955182 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 615
Study 3631471 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg
Number of subjects: 17
Study 3631471 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 5 mg
Number of subjects: 17
Study 3631471 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 5 mg
Number of subjects: 17
Study 3631471 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 29921538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning
Number of subjects: 1460
Study 27013513 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (tenofovir-emtricitabine)
Number of subjects: 515
Study 24065784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed seamless care program
Number of subjects: 0
Study 23772532 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose remifentanil (0.02, 0.05, and 0.07 microg x kg ‐1 x hr‐1)
Number of subjects: 52
Study 23772532 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose remifentanil
Number of subjects: 52
Study 20202912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support
Number of subjects: 442
Study 20202912 — intervention group
Group type: COMPARATOR
Intervention: Basic support
Number of subjects: 442
Study 20202912 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 442
Study 18979547 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, i.v. infusion for 3 consecutive weeks followed by 1-week rest)
Number of subjects: 49
Study 18979547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticancer intervention)
Number of subjects: 49
Study 18979547 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 49
Study 12195873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg b.i.d.
Number of subjects: 954
Study 12195873 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg b.i.d.
Number of subjects: 954
Study 9702844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Number of subjects: 37
Study 9702844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8040170 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced analgesia group comprising preincisional block and premedication with opiate and NSAID (Group 1)
Number of subjects: 56
Study 8040170 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional block, opiate premedication, and premedication with NSAID's
Number of subjects: 56
Study 8040170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 patients
Number of subjects: 56
Study 8040170 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced analgesic regime with NSAID and continuous extrapleural intercostal nerve block
Number of subjects: 56
Study 2742785 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cessation
Number of subjects: 402
Study 2742785 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term abstinence
Number of subjects: 402
Study 2742785 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of initial cessation
Number of subjects: 402
Study 2742785 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of long-term abstinence
Number of subjects: 402
Study 4422902 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse bran
Number of subjects: 0
Study 4422902 — intervention group
Group type: COMPARATOR
Intervention: Fine bran
Number of subjects: 0
Study 30705243 — intervention group
Group type: EXPERIMENTAL
Intervention: Short email with protocol attached
Number of subjects: 76
Study 30705243 — intervention group
Group type: COMPARATOR
Intervention: Long email without protocol attached
Number of subjects: 76
Study 28737593 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about the harms of smoking regarding fracture healing
Number of subjects: 20
Study 28737593 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 25942457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with someone other than primary partner and <100% condom use
Number of subjects: 1147
Study 25942457 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from sex in the previous month
Number of subjects: 1147
Study 25942457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with both primary and other partners and <100% condom use in nonpolygamous marriages
Number of subjects: 1147
Study 25942457 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one 72-hour gap in adherence
Number of subjects: 1147
Study 23204039 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab subcutaneously for 4 months
Number of subjects: 30
Study 23204039 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 30
Study 23204039 — intervention group
Group type: COMPARATOR
Intervention: control (topical therapies or phototherapy)
Number of subjects: 30
Study 21752481 — intervention group
Group type: EXPERIMENTAL
Intervention: 30Gy in 5 fractions (5.0Gy per fraction)
Number of subjects: 915
Study 21752481 — intervention group
Group type: EXPERIMENTAL
Intervention: 28.5Gy in 5 fractions (5.7Gy per fraction)
Number of subjects: 915
Study 21752481 — intervention group
Group type: COMPARATOR
Intervention: 50Gy in 25 fractions (2.0Gy per fraction)
Number of subjects: 915
Study 19729522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 89
Study 19729522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 16974199 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg GHB (Xyrem)
Number of subjects: 16
Study 16974199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 16
Study 16974199 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB plus ethanol
Number of subjects: 16
Study 15339684 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (50 UI/kg three times a week for 4 weeks; 20 UI/kg three times a week for 2 weeks)
Number of subjects: 10
Study 15339684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10931603 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting without predilatation
Number of subjects: 81
Study 10931603 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting with predilatation
Number of subjects: 81
Study 10931603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF, 300 micrograms subcutaneously
Number of subjects: 5
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF, 600 micrograms subcutaneously
Number of subjects: 5
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg orally
Number of subjects: 5
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF, 300 micrograms subcutaneously plus dexamethasone, 8 mg orally
Number of subjects: 5
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF, 600 micrograms subcutaneously plus dexamethasone, 8 mg orally
Number of subjects: 5
Study 9051093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (any dose)
Number of subjects: 5
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal P32
Number of subjects: 0
Study 8312118 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin
Number of subjects: 0
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (BEP)
Number of subjects: 0
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with irradiation
Number of subjects: 0
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field irradiation with weekly cisplatin
Number of subjects: 0
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy prior to pelvic radiotherapy
Number of subjects: 0
Study 8312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0
Study 31549519 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise (MET)
Number of subjects: 64
Study 31549519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 64
Study 28679168 — intervention group
Group type: EXPERIMENTAL
Intervention: High Heart Failure Risk Status (HFRS)
Number of subjects: 722
Study 28679168 — intervention group
Group type: COMPARATOR
Intervention: Low or medium Heart Failure Risk Status (HFRS)
Number of subjects: 722
Study 28679168 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic remote monitoring alerts
Number of subjects: 722
Study 25991608 — intervention group
Group type: EXPERIMENTAL
Intervention: snus
Number of subjects: 391
Study 25991608 — intervention group
Group type: COMPARATOR
Intervention: nicotine gum
Number of subjects: 391
Study 24806836 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich diet
Number of subjects: 19
Study 24806836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich diet
Number of subjects: 19
Study 24806836 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 19
Study 21930719 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved antihypertensive treatment
Number of subjects: 3534
Study 21179729 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengxue Mixture (SXM)
Number of subjects: 40
Study 21179729 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 40
Study 18426345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g)
Number of subjects: 1002
Study 18426345 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan (2 g)
Number of subjects: 1002
Study 16551150 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive therapeutic relationship early in treatment
Number of subjects: 0
Study 14519829 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (5 servings/day)
Number of subjects: 15
Study 10910858 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% lidocaine (1% lidocaine in sterile distilled water at a ratio of 1:3)
Number of subjects: 0
Study 10910858 — intervention group
Group type: COMPARATOR
Intervention: Neat 1% lidocaine
Number of subjects: 0
Study 8694205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 8694205 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study 1388091 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg TID (900 mg/day)
Number of subjects: 99
Study 1388091 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg BID (1000 mg/day)
Number of subjects: 99
Study 3986073 — intervention group
Group type: EXPERIMENTAL
Intervention: Finapres
Number of subjects: 0
Study 3986073 — intervention group
Group type: EXPERIMENTAL
Intervention: Accutorr
Number of subjects: 0
Study 3986073 — intervention group
Group type: COMPARATOR
Intervention: Intra-Arterial-Line
Number of subjects: 0
Study 31724891 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method with deeper breathing
Number of subjects: 40
Study 31724891 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method with talking
Number of subjects: 40
Study 31724891 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method with arm movement
Number of subjects: 40
Study 31724891 — intervention group
Group type: COMPARATOR
Intervention: Manual auscultatory method
Number of subjects: 40
Study 30131256 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN) 1500–2000 mg/d
Number of subjects: 3414
Study 30131256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3414
Study 30131256 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN)
Number of subjects: 3414
Study 26597421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component hospital pharmacist-led behavioural counselling and/or pharmacotherapy
Number of subjects: 600
Study 26597421 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine care provided by hospitals)
Number of subjects: 600
Study 23860945 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing
Number of subjects: 60
Study 23860945 — intervention group
Group type: COMPARATOR
Intervention: Rhythmic speaking
Number of subjects: 60
Study 23860945 — intervention group
Group type: COMPARATOR
Intervention: Speaking
Number of subjects: 60
Study 22980576 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO/footwear combination
Number of subjects: 10
Study 22980576 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 10
Study 20438786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)(2)D(3) treatment
Number of subjects: 32
Study 20438786 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 32
Study 17680290 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA meal with high cholesterol (PUFA‐HC)
Number of subjects: 16
Study 17680290 — intervention group
Group type: COMPARATOR
Intervention: Dairy fat (DF) meal
Number of subjects: 16
Study 17680290 — intervention group
Group type: COMPARATOR
Intervention: Type of meal (PUFA vs DF)
Number of subjects: 16
Study 15522756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 45S5 bioactive glass (10% solution), applied daily (2 x 1 h) during the preventive and therapeutic phase (21 days non-hygiene phase and 7 days therapeutic phase)
Number of subjects: 0
Study 15522756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 45S5 bioactive glass (10% solution)
Number of subjects: 0
Study 15522756 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral teeth without bioactive glass application)
Number of subjects: 0
Study 12043769 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ESWT (1500 pulses at 0.12 mJ/mm2)
Number of subjects: 74
Study 12043769 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 74
Study 10438968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination at birth
Number of subjects: 0
Study 10438968 — intervention group
Group type: COMPARATOR
Intervention: Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination later in life
Number of subjects: 0
Study 7598277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 58
Study 7598277 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 58
Study 2358274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aulhorn flicker test
Number of subjects: 405
Study 2358274 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP)
Number of subjects: 405